GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » Research & Development

Catalyst Pharmaceuticals (FRA:CN2) Research & Development : €86.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Catalyst Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Catalyst Pharmaceuticals's Research & Development for the three months ended in Mar. 2024 was €2.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €86.2 Mil.

Catalyst Pharmaceuticals Research & Development Historical Data

The historical data trend for Catalyst Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Research & Development Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.96 13.56 14.99 18.68 85.42

Catalyst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.33 3.65 78.39 1.81 2.38

Catalyst Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €86.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals  (FRA:CN2) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Catalyst Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Pharmaceuticals (FRA:CN2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » Research & Development
Comparable Companies
BEAM AGIO SNDX FUSN HRMY DNA INBX ZLAB SANA RXRX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
CPRX:USA
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Website
https://www.catalystpharma.com
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals (FRA:CN2) Headlines

No Headlines